UPDATE: Morgan Stanley Reiterates On HCA On Revised Outlook

In a report published Thursday, Morgan Stanley analyst Andrew Schenker reiterated an Overweight rating on HCA Holdings (NYSE: HCA), and raised the price target from $65.00 to $67.00.

In the report, Morgan Stanley noted, “HCA raised its EBITDA guidance to $7B to $7.15B reflecting TX Medicaid payments and an improved reform outlook. We updated our ‘14 EBITDA estimate to $7.15B, the high end of guidance, reflecting our expectations for a 2.8% reform benefit. We remain OW and raise our PT to $67.”

HCA closed on Wednesday at $60.99.